A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe ...

A new study has found small amounts of liquid ketamine administered in a clinical setting can significantly reduce symptoms ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...